Please login to the form below

Not currently logged in
Email:
Password:

Dutch companies partner on vaccines

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio. Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

Under the agreement, Immunovo will develop its therapeutic vaccine portfolio. Immunovo will pay an undisclosed cash sum to Pepscan and Pepscan will take a minority interest in Immunovo.

"Pepscan has recently refocused its R&D programme on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides," said Wim Mol, CEO of Pepscan.

"The agreement with Immunovo allows Pepscan to fully concentrate its resources on a focused execution of its research programme. We consider Immunovo an ideal partner to enhance the value of the therapeutic vaccine portfolio we have developed over the years."

Joost van Bree, CEO of Immunovo, said: "We are very pleased with the partnership with Pepscan on the therapeutic vaccine portfolio. Pepscan created a rich development pipeline of therapeutic vaccines, of which the most advanced product is in phase II clinical development.

"We are confident that with our specific expertise we will be able to expedite the development of this portfolio, which also includes a proprietary anti-VEGF-A vaccine that could be useful for the treatment of certain cancers."

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration.

28th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics